by CheckRare Staff | Jan 13, 2024
Robin Kate Kelley, MD, Professor of Clinical Medicine in the Division of Hematology/Oncology, University of California, San Francisco discusses treatment options for biliary tract cancers and the KEYNOTE-966 trial. Transcription: The KEYNOTE-966 trial was...
by Jake Ciszewski | Jan 12, 2024
Kimberly Moran, PhD, MBA, Head of US Rare Diseases at UCB, discuses new treatment options for myasthenia gravis, Transcription: One, we don’t make the clinical decisions. That’s what healthcare practitioners do. Most of their job is to really understand...
by CheckRare Staff | Jan 11, 2024
Björn Mellgård, MD, PhD, Vice President, Global Program Lead, Rare Genetics and Hematology, Takeda, discusses Adzynma ADAMTS13, recombinant-krhn (Adzynma), the first genetically engineered protein product indicated for prophylactic or on-demand enzyme replacement...
by Jake Ciszewski | Jan 10, 2024
Robin Kate Kelley, MD, Professor of Clinical Medicine Hematology/IOncology, University of California, San Francisco, describes the need for better treatment plans for patients with biliary tract cancer. Transcription: Interestingly, the perihelia and distal...
by CheckRare Staff | Jan 9, 2024
« Prev1 / 1Next »WHIM Syndrome: Overview, Diagnosis, and MagementWHIM Syndrome: Overview and Importance of Early Diagnosis (Chapter 1)Managing WHIM Syndrome (Chapter 2)Cancers and Screening Risks Associated With WHIM Syndrome (Chapter 3)« Prev1 /...
